中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
2期
290-292
,共3页
亓旭晨%王义荣%郭振涛%陈谦学%吴立权%杨树旭
亓旭晨%王義榮%郭振濤%陳謙學%吳立權%楊樹旭
기욱신%왕의영%곽진도%진겸학%오립권%양수욱
胶质瘤%多药耐药%拓扑异构酶Ⅱ
膠質瘤%多藥耐藥%拓撲異構酶Ⅱ
효질류%다약내약%탁복이구매Ⅱ
Glioma%Multidrug resistant%Topoisomerase Ⅱ
目的 观察拓扑异构酶Ⅱ(TopoⅡ)逆转胶质瘤多药耐药的效果.方法 依托泊苷诱导构建多药耐药细胞株U251/MDR,细胞计数试剂盒(CCK-8)法检测该细胞株的多药耐药性,逆转录-聚合酶链反应(RT-PCR)法检测TopoⅡ在U251和U251/MDR中的表达变化.采用小干扰RNA(siRNA)技术沉默耐药细胞株中TopoⅡ的表达后,检测其对化疗药物敏感性变化.结果 成功构建多药耐药细胞株U251/MDR,替莫唑胺、依托泊苷、长春新碱、阿霉素、环磷酰胺对U251/MDR的半数抑制浓度(IC50)分别为:(12.58±0.53)、(12.41±0.49)、(3.98±0.38)、(4.13±0.28)、(20.88±0.62) mg/L,对亲本细胞U251的IC50值分别为:(3.42±0.36)、(3.86±0.22)、(2.14±0.25)、(1.87±0.09)、(5.35±0.37) mg/L,U251/MDR中TopoⅡ的表达明显升高,沉默TopoⅡ的表达后,耐药性被成功逆转,沉默前后替莫唑胺、依托泊苷、长春新碱、阿霉素、环磷酰胺对其的IC50值分别为:(13.16±0.45)/(4.58 ±0.27)、(12.18±0.39)/(4.96±0.18)、(3.87 ±0.27)/(2.36±0.15)、(4.86±0.19)/(1.24±0.08)、(19.96±0.56)/(7.38±0.24) mg/L.结论 TopoⅡ可以逆转胶质瘤的多药耐药性.
目的 觀察拓撲異構酶Ⅱ(TopoⅡ)逆轉膠質瘤多藥耐藥的效果.方法 依託泊苷誘導構建多藥耐藥細胞株U251/MDR,細胞計數試劑盒(CCK-8)法檢測該細胞株的多藥耐藥性,逆轉錄-聚閤酶鏈反應(RT-PCR)法檢測TopoⅡ在U251和U251/MDR中的錶達變化.採用小榦擾RNA(siRNA)技術沉默耐藥細胞株中TopoⅡ的錶達後,檢測其對化療藥物敏感性變化.結果 成功構建多藥耐藥細胞株U251/MDR,替莫唑胺、依託泊苷、長春新堿、阿黴素、環燐酰胺對U251/MDR的半數抑製濃度(IC50)分彆為:(12.58±0.53)、(12.41±0.49)、(3.98±0.38)、(4.13±0.28)、(20.88±0.62) mg/L,對親本細胞U251的IC50值分彆為:(3.42±0.36)、(3.86±0.22)、(2.14±0.25)、(1.87±0.09)、(5.35±0.37) mg/L,U251/MDR中TopoⅡ的錶達明顯升高,沉默TopoⅡ的錶達後,耐藥性被成功逆轉,沉默前後替莫唑胺、依託泊苷、長春新堿、阿黴素、環燐酰胺對其的IC50值分彆為:(13.16±0.45)/(4.58 ±0.27)、(12.18±0.39)/(4.96±0.18)、(3.87 ±0.27)/(2.36±0.15)、(4.86±0.19)/(1.24±0.08)、(19.96±0.56)/(7.38±0.24) mg/L.結論 TopoⅡ可以逆轉膠質瘤的多藥耐藥性.
목적 관찰탁복이구매Ⅱ(TopoⅡ)역전효질류다약내약적효과.방법 의탁박감유도구건다약내약세포주U251/MDR,세포계수시제합(CCK-8)법검측해세포주적다약내약성,역전록-취합매련반응(RT-PCR)법검측TopoⅡ재U251화U251/MDR중적표체변화.채용소간우RNA(siRNA)기술침묵내약세포주중TopoⅡ적표체후,검측기대화료약물민감성변화.결과 성공구건다약내약세포주U251/MDR,체막서알、의탁박감、장춘신감、아매소、배린선알대U251/MDR적반수억제농도(IC50)분별위:(12.58±0.53)、(12.41±0.49)、(3.98±0.38)、(4.13±0.28)、(20.88±0.62) mg/L,대친본세포U251적IC50치분별위:(3.42±0.36)、(3.86±0.22)、(2.14±0.25)、(1.87±0.09)、(5.35±0.37) mg/L,U251/MDR중TopoⅡ적표체명현승고,침묵TopoⅡ적표체후,내약성피성공역전,침묵전후체막서알、의탁박감、장춘신감、아매소、배린선알대기적IC50치분별위:(13.16±0.45)/(4.58 ±0.27)、(12.18±0.39)/(4.96±0.18)、(3.87 ±0.27)/(2.36±0.15)、(4.86±0.19)/(1.24±0.08)、(19.96±0.56)/(7.38±0.24) mg/L.결론 TopoⅡ가이역전효질류적다약내약성.
Objective To investigate the effect of topoisomerase Ⅱ (Topo Ⅱ) reversing the multidrug resistance in glioma.Methods Multidrug resistant cell line was constructed and the expression of Topo Ⅱ was detected by using reverse transcription-polymerase chain reaction (RT-PCR).The multidrug resistance was detected by cell counting kit-8 (CCK-8).Topo Ⅱ was silenced in resistant cell line,then the chemotherapy sensitivity was tested.Results The multidrug resistant cell line was constructed,the IC50 of U251/MDR to temozolomide,eToposide,vincristine,adriamycin,and cyclophosphamide was (12.58 ±0.53),(12.41±0.49),(3.98 ±0.38),(4.13±0.28),(20.88 ±0.62) mg/L,and that of U251 to these drugs was (3.42 ± 0.36),(3.86 ± 0.22),(2.14 ± 0.25),(1.87 ± 0.09) and (5.35 ±0.37) mg/L respectively.The expression of Topo Ⅱ was increased in U251/MDR cells as compared with U251 cells,and the resistance was abolished after silencing Topo Ⅱ in the resistant cells.The IC50 of U251/MDR and U251 to temozolomide,eToposide,vincristine,adriamycin,cyclophosphamide was (13.16±0.45)/(4.58±0.27),(12.18 ±0.39)/(4.96 ±0.18),(3.87 ±0.27)/(2.36±0.15),(4.86 ± 0.19)/(1.24 ± 0.08),and (19.96 ± 0.56)/(7.38 ± 0.24) mg/L respectively.Conclusion Topo Ⅱ can reverse the multidrug resistance in glioma.
